The Peter Attia Drive

In this episode, Peter welcomes back Jeff Cavaliere, a physical therapist, strength coach, and founder of ATHLEAN-X who has spent decades bridging the gap between rehabilitation, athletic performance, and strength training. Jeff begins by sharing how his experience working with professional athletes and managing his own injuries has shaped his approach to building strength and muscle while minimizing injury risk. He discusses how training should evolve as we age, particularly for those in their 40s, 50s, and beyond who want to continue making progress without compromising long-term joint health. Jeff explains why excessive training volume can be counterproductive and how to balance reps in reserve with training to failure to maximize results while managing fatigue and injury risk. He also explores the differences between training for aesthetics and functional performance, explaining why these goals are not necessarily at odds. The conversation then shifts to a muscle-by-muscle breakdown of effective exercises for building strength and hypertrophy. Jeff highlights common training mistakes, offers modifications for those dealing with pain or injury, and explains why often-neglected muscles deserve more attention. Finally, he walks through his "exercise graveyard," identifying popular exercises that may carry unnecessary injury risk and offering alternatives that deliver similar benefits with less risk. Throughout the episode, Jeff provides actionable guidance for making training more effective, sustainable, and adaptable as we age.

We discuss:

• Jeff's passion as an educator and the path that led him to build his YouTube channel [2:30];
• Jeff's injury history and how he overcomes injury in training [11:00];
• Qualities of great athletes and the tragedy of injury [20:15];
• Tom Brady—an example of the value of pliability and consistency [24:30];
• The athlete's mindset, how training changes in midlife, and the importance of a warm-up [28:15];
• Reducing risk of injury in middle age and beyond: reps in reserve, training to failure, and junk volume [35:15];
• How training intensity changes in midlife [44:30];
• Hypertrophy: misconceptions and common mistakes when training shoulders [48:15];
• Deltoid muscles of the shoulder: exercises beyond the overhead press [59:45];
• Triceps: compound movements and exercises that target the long head [1:11:15];
• Upper arm: best approaches for building hypertrophy and strength [1:21:00];
• Biceps: nuance around training [1:24:30];
• Forearm exercises that target the flexors and brachioradialis [1:31:45];
• Pecs and chest: pressing and crossover movements [1:34:15];
• Great abs: nutrition, rotation exercises, interval training, and more [1:45:30];
• Back: exercises to create that V-shape [1:52:30];
• Legs: training the quads, glutes, and more [2:02:00];
• Calves: training the gastrocnemius and soleus [2:13:00];
• Jeff's "exercise graveyard" and recommendations for modifications that achieve results with less risk of injury [2:21:00]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Nov 2, 2026 2 hr 29 min

#413 ‒ The neuroscience of emotion: challenging conventional theories of emotion, how the brain predicts and constructs our experiences, and gaining greater control over how we feel | Lisa Feldman…

Episode 413

Show notes

In this episode, Peter sits down with Dr. Lisa Feldman Barrett, a psychologist, neuroscientist, author, and distinguished professor at Northeastern University whose research challenges many of the conventional assumptions about emotions and how the brain works. Lisa is best known for her theory of constructed emotion, which challenges the idea that emotions such as fear, anger, and sadness are hardwired responses with universal biological signatures. She begins by explaining how unexpected findings early in her research led her to question traditional theories of emotion. She discusses why studying individual variation, rather than relying on averages, is essential to understanding the brain. Lisa then explores the idea that the brain is fundamentally a predictive system rather than a reactive one. She explains how past experiences and memories shape what we perceive, feel, and do. She also describes how the brain continuously anticipates and regulates metabolism through a process called allostasis. The conversation then turns to the effects of chronic stress, uncertainty, and childhood adversity on physical and emotional health. Lisa explains how our relationships help regulate our nervous systems and why the loss of a loved one can have such a profound physiological impact. She also discusses how deliberate practice and new experiences can reshape the brain's predictions, potentially changing how we think, feel, and respond to the world around us. Throughout the discussion, Peter and Lisa explore how this framework challenges traditional views of emotion and offers a greater sense of agency over our emotional lives.

We discuss:

• How unexpected results in graduate school changed Lisa's understanding of emotion [3:30];
• Why variation is the norm for emotion, and the danger in tracking averages instead of characterizing variation [15:30];
• Lisa's experience with Hashimoto's disease and the value of modeling individual variation [30:00];
• How Lisa's research challenges common views about emotions, and why there is no biomarker for emotions [40:00];
• The difficulty of defining emotions and the brain's role in regulating the body [49:15];
• Consciousness, interoception, and the limits of subjective experience [54:00];
• Defining emotion: fear and anger [1:00:15];
• The brain as a predictive system rather than a reactive one [1:13:15];
• Baseball as an example of the brain's predictive nature [1:31:00];
• How the human brain differs from that of other animals [1:44:00];
• The impact of stress on metabolism, and the role of the brain in maintaining allostasis [1:49:45];
• Childhood adversity, social regulation of the nervous system, and the effect of chronic stress [1:56:45];
• Understanding chronic stress: why some people respond differently, and its impact on metabolism [2:02:15];
• How practicing new predictions can change thoughts and feelings [2:10:15];
• Lisa's practice of finding awe in everyday experiences and the greater sense of agency it brings [2:13:30];
• The impact of grief on nervous system regulation and the metabolic "body budget," as well as practices that reduce sadness [2:22:15];
• The connection between memories and predictions, and Peter's closing thoughts [2:29:45]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Oct 26, 2026 2 hr 34 min

#412 ‒ The evolving science of cancer: emerging approaches to prevention and early detection, and the advances reshaping treatment | Siddhartha Mukherjee, M.D., Ph.D.

Episode 412

Show notes

In this episode, Peter welcomes back Dr. Siddhartha Mukherjee, a physician, oncologist, researcher, and the Pulitzer Prize-winning author of The Emperor of All Maladies. Fifteen years after the book was first published, Sid released an updated edition. This conversation examines what has changed in our understanding of cancer—not only in how we treat it, but in how we think about its causes, prevention, detection, and biology. Sid explores the contributions of genetics, environmental exposures, random mutations, and inflammation to cancer risk, including the emerging role of hyperinsulinemia and metabolism. He discusses why detecting cancer early remains so difficult, particularly in pancreatic cancer, and how advances in immunotherapy, CAR T cell therapy, and targeted treatments such as KRAS inhibitors are changing the treatment landscape. The conversation then broadens beyond cancer to what Sid calls "regenerative failure"—the declining ability of tissues to repair and replenish themselves with age. Peter and Sid explore how this process may contribute to conditions such as osteoarthritis, and whether longevity should be approached less as the prevention of individual diseases and more as the preservation of regenerative capacity. Sid weighs in on the potential for chemoprevention, metabolic interventions, and AI to transform cancer prevention and treatment. Finally, they discuss what it would take to develop meaningful biomarkers of longevity that could ultimately help to extend human healthspan and lifespan.

We discuss:

• What oncology has learned in the 15 years since The Emperor of All Maladies was published [2:45];
• The contributions of genetic risk, bad luck, and inflammation to cancer [14:45];
• The role of metabolism and hyperinsulinemia in cancer [31:00];
• Osteoarthritis: the role of inflammation and regenerative stem cells [40:45];
• How cancer escapes the immune system—the subtleties of neoantigens and immune checkpoints [49:45];
• AI and the thymus as a predictor of longevity, and T cell aging and immune regeneration [57:15];
• How CAR T cell therapy works and why solid tumors are harder to treat [1:04:00];
• Targeting KRAS in pancreatic cancer [1:10:45];
• The rise of colorectal cancer in younger adults [1:19:15];
• How AI may transform drug discovery [1:23:00];
• The future of cancer prevention: chemoprevention [1:33:15];
• Challenging the current model of longevity—disease prevention versus targeting regenerative failure [1:37:45];
• The need for a biomarker of longevity—comparing geroscience to atherosclerosis [1:50:30];
• Clinical trials targeting cancer metabolism [1:56:00];
• What Sid is currently writing about and a glimpse into his writing process [1:58:00]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Oct 19, 2026 2 hr 4 min

#411 ‒ AMA #90: Strong convictions, loosely held: how Peter's views on fasting, keto, metformin, rapamycin, whole-body MRI, and exercise have changed

Episode 411

Show notes

In this "Ask Me Anything" (AMA) episode, Peter looks back on 400 episodes of The Drive with another installment of "strong convictions, loosely held," revisiting some of the positions he has taken over more than eight years of the podcast. He explains why changing one's mind in response to new evidence, conversations with experts, and clinical experience is essential for practicing medicine well. Peter begins with nutrition, describing how his views on ketogenic diets, extended fasting, and the framework of dietary restriction, time restriction, and calorie restriction have evolved. He explains why he no longer takes metformin for longevity and discusses his growing uncertainty around rapamycin despite compelling animal data. Peter also revisits his views on cancer screening, including whole-body MRI and liquid biopsies for early detection. On exercise, Peter explains how his approach to cardiorespiratory training and the 80/20 Zone 2 framework has changed, particularly for people with limited time to train. He also shares why he has moved away from heavy barbell squats and deadlifts and how he now thinks about balancing benefit and injury risk. Throughout the episode, Peter emphasizes the importance of focusing on durable principles, strong foundations, and sustainable practices rather than chasing optimizations that provide marginal gains.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #90 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

• Strong convictions, loosely held: changing opinions as evidence, expert conversations, and clinical experience evolve [2:00];
• Nutrition: Peter's evolving view of ketogenic diets, energy balance, and dietary dogmatism [5:30];
• Extended fasting, autophagy, lean-mass loss, and who may benefit from prolonged fasting [12:00];
• The dietary restriction, time restriction, and calorie restriction framework—and why GLP-1 agonists are tipping the balance toward calorie restriction [20:15];
• Why Peter no longer views metformin as geroprotective for metabolically healthy people [24:45];
• Rapamycin for longevity: compelling animal data, unresolved human dosing, and Peter's growing uncertainty [29:15];
• The importance of early cancer detection, declining whole-body magnetic resonance imaging (MRI) quality, and more targeted alternatives [41:30];
• Liquid biopsies for cancer screening: the NHS-Galleri trial, why early-stage rather than late-stage detection is what actually matters, and why the technology remains "fuzzy" [53:30];
• Evolving exercise goals, the limitations of the 80/20 Zone 2 framework, and programming cardio at lower training volumes [1:00:00];
• Exercise prescriptions for limited time, building a training habit, and becoming less dogmatic about forcing workouts [1:05:00];
• Moving away from heavy squats and deadlifts, alternative exercises, and deliberate risk management [1:13:00];
• Prioritizing principles, foundations, and sustainable practices over marginal optimization [1:21:30]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Oct 12, 2026 18 min

#410 ‒ The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia, childbirth, and long-term maternal health | Kathryn Gray, M.D., Ph.D.

Episode 410

Show notes

In this episode, Peter sits down with Dr. Kathryn (Katie) Gray, a physician-scientist, high-risk obstetrician, and maternal-fetal medicine specialist at the University of Washington School of Medicine. Katie begins by explaining the remarkable physiologic changes that occur during pregnancy and how the cardiovascular, metabolic, and hormonal systems adapt to support both mother and developing fetus. From there, the conversation turns to some of the most important complications that can arise. Katie explains how gestational diabetes is screened for and treated, and what a diagnosis may mean for the long-term health of both mother and child. She then walks through the biology of preeclampsia, including who is at risk and how the condition is managed. She also discusses HELLP syndrome and postpartum depression. Peter and Katie explore the realities of labor and delivery, including breech presentation, the role of midwives, and the trade-offs between vaginal and cesarean delivery. The conversation also covers stillbirth and the growing role of cell-free DNA in prenatal genetic screening. Other topics include prenatal nutrition and folate, breastfeeding, and exercise during pregnancy. Throughout the episode, Peter and Katie return to a larger question: What can pregnancy reveal about a woman's long-term health? They discuss how complications during pregnancy can provide important clues about future health risks. Finally, Katie highlights some of the major questions that remain unanswered in maternal health and why greater investment in research is needed to improve outcomes for mothers and their children.

Disclaimer: The views expressed on this podcast are solely those of Dr. Kathryn Gray and do not represent the University of Washington or any of its affiliated units. Dr. Gray speaks solely in a personal capacity, and nothing here should be construed as an official position or endorsement from the University of Washington.

We discuss:

• What drew Katie to obstetrics and gynecology, and fundamental questions in the field that remain unanswered [3:15];
• Pregnancy as a cardiovascular and metabolic stress test; the first symptoms and early changes [6:30];
• Early hormonal changes, prenatal nutrition, and neural tube defects [16:00];
• Fetal development and the physiology of gestational diabetes [23:45];
• Diagnosing and treating gestational diabetes [30:00];
• Preeclampsia: diagnosis, biology, acute risk, and how it's managed [37:00];
• HELLP syndrome, what genetic studies reveal about preeclampsia, and the antihypertensive medications used to treat it [49:00];
• What pregnancy reveals about long-term cardiometabolic health [54:45];
• Cesarean delivery, breech presentation, and stillbirth [1:01:15];
• The onset of labor, cervical dilation, and membrane rupture [1:14:15];
• Vaginal delivery and breastfeeding: benefits versus myths [1:23:15];
• Exercise during pregnancy, sleep position in the third trimester, and postpartum depression [1:27:00];
• Prenatal genetic screening: the growing role of cell-free DNA and the gap between what is technologically possible and what gets deployed in the clinic [1:33:00];
• Midwifery and the realities of childbirth [1:39:00];
• Maternal health in the United States and the need for research investment [1:48:30]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Oct 5, 2026 1 hr 58 min

#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.

Episode 409

Show notes

Lloyd B. Klickstein is a physician-scientist who has spent more than 20 years at the intersection of drug discovery, healthy aging, and preventive medicine. Drawing on his experience in academic medicine, translational research, and biotechnology, Lloyd walks through the full arc of modern drug development. He explains how scientists identify an unmet medical need and decide which diseases and therapeutic targets are worth pursuing. From there, he takes us through the process of engineering a drug, testing it in animals, and navigating clinical trials and regulatory approval. Using bimagrumab as a case study, Lloyd explains the rationale for targeting myostatin and activin signaling to increase muscle mass and strength and describes how the antibody was engineered and screened. He then walks through what was learned from early clinical trials. Unexpected effects on fat mass and type 2 diabetes helped reshape bimagrumab's development as a potential treatment for obesity, including its use in combination with semaglutide. Along the way, Peter and Lloyd explore the differences among drug modalities, including biologics and small-molecule therapeutics. They discuss the roles of patents and capital allocation in drug development, along with the requirements for IND submission and GMP manufacturing. They also examine why developing a new drug takes so long and costs so much, and why identifying failures early is critical. At the end of the episode, the conversation turns to mTOR inhibition and geroprotection, as well as Lloyd's current work on a novel pharmacologic approach to cancer prevention. This episode provides a rare behind-the-scenes look at how new medicines are actually created and the scientific, regulatory, and economic decisions that determine which ideas ultimately make it to patients.

We discuss:

• Lloyd's path from academic medicine to translational drug development [3:15];
• Drug modalities, patents, and the economics of innovation [11:30];
• Choosing sarcopenia as a target for drug development, and confronting the problem of measuring falls [23:00];
• The rationale for bimagrumab: improving muscle mass and strength by targeting myostatin and activin signaling (and why follistatin failed) [36:45];
• Engineering and screening the bimagrumab antibody, and the cost of developing a new drug [43:45];
• From candidate antibodies to animal proof of concept (impressive muscle hypertrophy) [54:15];
• Toxicology, capital allocation, and the path to an IND [1:02:45];
• IND requirements, GMP manufacturing, and gray market peptides [1:14:45];
• First in-human study design, patient selection, and protection of healthy volunteers [1:22:00];
• Phase 1 dosing, pharmacodynamics, and global trial strategy [1:33:45];
• Phase 2 lessons on muscle mass, function, and nutrition [1:43:30];
• Bimagrumab's effects on fat mass and type 2 diabetes [1:50:45];
• The BELIEVE trial of bimagrumab plus semaglutide [1:59:30];
• Selective mTORC1 inhibition and the challenge of testing geroprotection [2:11:45];
• A new pharmacologic approach to cancer prevention [2:15:45]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Sep 28, 2026 2 hr 26 min

#408 ‒ AMA #89: Thyroid health: interpreting symptoms, diagnosing and treating dysfunction, and navigating the gray zone

Episode 408

Show notes

In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into thyroid health and explains why diagnosing and managing thyroid dysfunction is unusually complex. He begins with the basic biology of the thyroid gland and three commonly measured hormones—free T4, free T3, and TSH. He explains how T4 is converted to the active hormone T3 and the important functions T3 performs throughout the body. He also explains what reverse T3 is and when it may be useful to measure it. Peter then breaks down thyroid blood tests and their limitations and provides a practical framework for evaluating suspected thyroid dysfunction. He explains why symptoms alone are insufficient for diagnosis and reviews the criteria for diagnosing hypothyroidism, along with conditions that can mimic it. He also explores how hypothyroidism can be both underdiagnosed and overtreated and how to navigate subclinical hypothyroidism. Peter discusses treatment with T4 and T3, including why some patients continue to experience symptoms despite standard T4 replacement. He also explains how thyroid medications should be taken to optimize absorption. Additional topics include Hashimoto's disease, thyroid considerations during pregnancy, hyperthyroidism, the risks of excess iodine, and supplements marketed to support thyroid function. Finally, Peter offers guidance for patients who continue to feel unwell despite apparently normal thyroid tests.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feedor our website at the AMA #89 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

• Why thyroid management is unusually complex and what the thyroid does [2:00];
• Why symptoms are insufficient for diagnosis and the risks of underdiagnosis and overtreatment [9:00];
• Regulation of the thyroid axis and conversion of T4 to T3 [13:30];
• Reverse T3 and the metabolic effects of T3 [20:00];
• Thyroid blood tests, assay limitations, and who should be tested [22:45];
• Causes and mimics of hypothyroidism and the criteria for diagnosis [29:00];
• Navigating subclinical hypothyroidism [34:30];
• Treating hypothyroidism with T4 and T3 [37:00];
• Hashimoto's disease, pregnancy, and associated autoimmune risks [42:45];
• Proper timing and administration of thyroid medication [43:45];
• Causes, symptoms, diagnosis, and treatment of hyperthyroidism [45:15];
• Iodine excess, the risks of thyroid-support supplements, and evidence for dietary interventions [53:45];
• A practical framework for evaluating and treating patients who suspect thyroid dysfunction [59:30]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Sep 21, 2026 16 min

#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

Episode 407

Show notes

Michael Davidson is a world-renowned cardiologist, lipidologist, and the founding CEO of NewAmsterdam Pharma. He begins this episode by sharing how his family history shaped his interest in lipidology and primary prevention. He explains why prevention should focus on causal drivers of disease rather than near-term risk and examines the causal relationship between LDL and atherosclerotic cardiovascular disease. Michael then traces the complicated history of CETP inhibitors—from the original rationale that raising HDL would reduce cardiovascular risk to the failures of torcetrapib, dalcetrapib, and evacetrapib—and explains how lessons from these trials ultimately led to the development of obicetrapib. He reviews the phase 2 and phase 3 trials of obicetrapib, its effects on LDL-C, apoB, LDL particle number, and Lp(a), the ongoing cardiovascular outcomes trial, and where the drug could fit alongside statins and other lipid-lowering therapies. Peter and Michael discuss the relationship between statins and diabetes risk, then turn to the potential role of obicetrapib in Alzheimer's disease prevention, exploring the genetics of APOE4 and CETP, cholesterol metabolism within the brain, and emerging biomarker data. Finally, Peter and Michael explore the benefits of omega-3 fatty acids and the challenge of delivering DHA to the brain, as well as ongoing work on klotho in preparation for clinical trials. They discuss the potential for AI to transform clinical trials and the scientific and financial challenges of developing new therapies for cardiovascular and neurodegenerative disease.

We discuss:

• Michael's path to lipidology, and his passion for primary prevention [3:30];
• Reframing prevention around causal drivers rather than time horizon [9:30];
• What CETP inhibition does, the evolutionary biology of CETP, the HDL-raising rationale, and Pfizer's torcetrapib failure [15:00];
• Why raising HDL is thought to be beneficial, a quick review of the functions of HDL, and how this connects to torcetrapib [24:00];
• The graveyard of CETP inhibitors: Roche's dalcetrapib, Lilly's evacetrapib, and Merck's REVEAL trial [27:15];
• The causality of LDL in cardiovascular disease [34:30];
• Reviving obicetrapib at NewAmsterdam, and confirming the benefit is LDL lowering: the TULIP data, the abandoned statin-intolerance path, and the Mendelian randomization verdict on HDL [37:30];
• Phase 2 and phase 3 trials of obicetrapib—ROSE, BROOKLYN, BROADWAY, and TANDEM—and the PREVAIL outcomes trial, with the European and US approval paths [44:45];
• Discordance among LDL-C, LDL-P, and apoB with CETP inhibition, and obicetrapib's Lp(a)-lowering effect [50:30];
• Where obicetrapib fits in the lipid-lowering toolkit, the case against high-dose statins, and the problem of drug pricing [57:30];
• The case for obicetrapib in Alzheimer's: the APOE4 and CETP genetics, the animal models, and funding Alzheimer's research [1:03:45];
• Brain cholesterol metabolism and the APOE4 mechanism: the blood-brain barrier, astrocyte cholesterol efflux, the amyloid-tau cascade, the role of HDL, and why statins don't cause Alzheimer's disease [1:08:00];
• The biomarker evidence: the CSF pilot study, Alzheimer's as a disease of middle age, the pharma graveyard problem, and the p-tau 217 results from BROADWAY [1:17:45];
• Whether obicetrapib translates into clinical benefit for Alzheimer's disease: the risk of fooling yourself, the persistence of the amyloid dogma, ARIA in APOE4 homozygotes, and the next prevention trial [1:28:00];
• Fish oil, EPA, and DHA: the cardiovascular trials and the challenge of delivering DHA to the brain [1:32:00];
• Two open problems: using AI to reform clinical trials, and the statin–diabetes signal [1:41:15];
• What it takes to develop a drug, the biotech investment landscape, and the klotho program [1:48:15];
• Closing reflections: what to do if you carry APOE4, balancing motivation against over-testing, and the need for multiple therapies [1:55:15]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Sep 14, 2026 1 hr 59 min

Blood pressure: how to measure, manage, and treat high blood pressure (AMA #48 rebroadcast)

Show notes

In this "Ask Me Anything" (AMA) episode, Peter delves into the critical subject of blood pressure, which is one of the three primary causes of atherosclerosis, along with high apoB and smoking. He begins by unraveling the nature of high blood pressure, its prevalence, and why it often goes undiagnosed. Peter describes in detail the proper way to accurately measure blood pressure and what determines a diagnosis. Next, Peter discusses the actionable steps one can take in response to high blood pressure, shedding light on the extent to which factors like weight loss, exercise, and nutrition can make an impact. He also explores the pharmacological options available and offers valuable insights on how to approach them.

We discuss:

• Blood pressure and other risk factors for cardiovascular disease [2:30];
• Defining blood pressure and the purpose and meaning of a blood pressure measurement [5:45];
• The implications of high blood pressure and the importance of maintaining an optimal level [10:30];
• The importance of accurate measurements of blood pressure and how Peter approaches the care of patients at the very top range of "normal" [21:45];
• The prevalence of high blood pressure—a hidden epidemic? [24:30];
• The consequences of high blood pressure on cardiovascular health, brain health, kidneys, and more [24:45];
• Low blood pressure: symptoms and consequences [35:30];
• How to properly measure blood pressure [37:45];
• Daily variance in blood pressure and the transient changes in blood pressure during exercise [48:00];
• Primary hypertension vs. secondary hypertension: what to look for [51:45];
• Lifestyle factors impacting blood pressure: weight loss, exercise, and sodium [57:45];
• Impact of insulin resistance and type 2 diabetes on blood pressure [1:04:45];
• How sleep impacts blood pressure [1:06:45];
• Pharmacologic options for managing blood pressure [1:08:00]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Sep 7, 2026 1 hr 17 min

#406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D.

Episode 406

Show notes

Brian Grosberg is a world-renowned headache specialist who joins Peter to provide a master class on the diagnosis and treatment of headache disorders. In this episode, Brian explains the distinction between primary and secondary headaches and breaks down the defining features of the "big three" primary headache types (migraine, cluster, and tension headache)—highlighting how often they are misdiagnosed and how they are treated. He explores the epidemiology of headaches, describing migraine as an invisible disease affecting about 12% of the population, disproportionately affecting women, while cluster headaches more often affect men. He discusses the major gap between demand for headache care and available specialists, and he offers advice on when to see a physician. Brian dives into the multifactorial nature and pathophysiology of migraine, including genetic and hormonal influences, neurovascular changes, and inflammatory signaling, and connects these mechanisms to modern therapies. Throughout the conversation, he emphasizes the individualized nature of headache disorders and the importance of a detailed headache diary. Brian shares practical strategies for treating headaches including lifestyle changes, medications, and neuromodulation devices.

We discuss:

• Brian's interest in headaches and how Peter met Brian [2:15];
• Differentiating the types of headaches: primary versus secondary headache and tension versus migraine headache [7:30];
• The epidemiology and burden of migraine, its disproportionate affect on women, and the shortage of headache specialists [20:00];
• Genetic susceptibility to migraine and the role of hormones [24:45];
• Migraine triggers, the impact of hormones, and the importance of a headache diary [31:15];
• The phases of a migraine: premonitory symptoms, aura, the headache itself, and the postdrome [38:15];
• Tension headaches: symptoms, causes, and prevalence [41:45];
• Cluster headaches: extreme pain, distinctive symptoms, and frequent misdiagnosis as a sinus infection or allergies [43:15];
• Lifestyle interventions to prevent headaches [51:15];
• Pharmacological treatments to prevent headaches [1:05:00];
• What's known about the pathophysiology of migraines: neurovascular changes, release of neuropeptides, and inflammatory response [1:14:45];
• CGRP antagonists for the treatment of migraines: large monoclonal antibodies and gepants [1:20:15];
• Use of calcium channel blockers and Botox to treat cluster headache and migraine [1:28:30];
• Drugs for the acute treatment of migraines [1:32:30];
• Treatment of migraines with electrical stimulation devices [1:40:00];
• Use of THC or cannabis to treat headaches [1:44:00];
• What Brian wants people to know about headaches [1:45:45];
• Brian's advice on when to see a doctor about headaches and how to prepare for that visit [1:49:15]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Aug 31, 2026 1 hr 56 min

#405 ‒ AMA #88: Metabolic liver health: how to assess risk, catch dysfunction early, and prevent or reverse liver disease

Episode 405

Show notes

In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into the liver and its central role in metabolic health. He explains why the liver can serve as a "canary in the coal mine" for metabolic dysfunction and explores how insulin resistance, visceral fat, alcohol consumption, genetics, and hormones contribute to liver disease, along with how increasing muscle mass can benefit liver health. Peter provides a framework for understanding the progression of liver disease, highlighting which stages are reversible and why early detection matters. He explains why normal liver enzymes can provide false reassurance, which labs he uses to assess liver health, and the tools available for detecting fibrosis and more advanced disease. Peter then breaks down the interventions that can meaningfully improve liver health once risk or disease is identified, ranging from diet and exercise to GLP-1–based therapies and other medications. Finally, he examines popular claims around liver "detoxification" and supplements, separating what is supported by evidence from what is unlikely to meaningfully improve liver health.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feedor our website at the AMA #88 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

• Why the liver is the "canary in the coal mine" for metabolic dysfunction, and an overview of what the liver does [2:00];
• The relationship between the liver and blood sugar control [6:30];
• A framework for understanding how metabolic disease affects the liver [9:15];
• Chronic caloric surplus and insulin resistance as drivers of liver disease [11:00];
• Liver diseases that result from metabolic dysfunction and the difference between steatosis and fibrosis [15:15];
• How visceral fat affects liver health [20:00];
• The importance of lifestyle interventions for liver and metabolic health: resistance training, not drinking calories, and the impact of fructose [22:00];
• Why alcohol-associated liver disease is more common than we give it credit for [26:30];
• Genetic and hormonal risks for liver disease [31:45];
• Labs that objectively measure liver health and the FIB-4 score [35:30];
• FibroScan: non-invasive imaging of the liver [44:30];
• The resiliency of the liver: an organ that can heal itself [47:00];
• Fibrosis staging and its impact on mortality and cancer risk [49:15];
• Interventions for someone with MASLD: weight loss and GLP-1s [52:00];
• Other medications used to treat metabolic liver disease [57:00];
• The role of exercise in treating metabolic liver disease: caloric deficit and building muscle [59:45];
• The myth of liver detoxes and cleanses, and a few supplements that may benefit the liver [1:01:15];
• A practical summary: how to assess your risk and the levers that reverse the disease [1:08:00]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Aug 24, 2026 39 min

#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.

Episode 404

Show notes

In this episode, Peter sits down with Dr. Linus Abrams, a psychiatrist with nearly 35 years of clinical experience specializing in mood disorders and psychopharmacology, to explore how our understanding of mental health is evolving beyond the traditional neurotransmitter model. After decades in practice, Linus began questioning many of the assumptions underlying modern psychiatry, leading him to investigate how hormones, metabolism, inflammation, circadian biology, and the endocrine system shape mood and cognition. Together, Peter and Linus examine why psychiatric care should aim not only to reduce symptoms but also to restore the full human experience. They discuss how psychiatric medications work, where they fall short, and why distinguishing bipolar disorder from unipolar depression is essential for effective treatment. The conversation also explores the growing mental health burden of social isolationn associated with digital devices and social media, along with the biological factors—nutrition, exercise, sleep, and chronic stress—that influence resilience and distress tolerance. Linus explains the powerful roles of estrogen, progesterone, testosterone, and thyroid hormone in regulating mood and cognition across the lifespan. Finally, Peter and Linus review the promise and limitations of ketamine and psychedelic therapies, and why the future of psychiatry may lie in integrating neuroscience, endocrinology, and whole-body physiology to better understand, diagnose, and treat mental illness.

We discuss:

• Linus's passion for understanding his patients and going beyond traditional psychiatry [2:45];
• A short primer on the different classes of drugs used in psychiatry [12:45];
• Evaluation of a patient with bipolar disorder [26:00];
• An evolutionary perspective on depression [33:30];
• Changes in the modern world triggering mental health problems [41:00];
• An evolutionary perspective on insomnia [48:15];
• Peter's window analogy to understand distress tolerance and irritability [49:45];
• The impact of foundational biological factors on psychiatry: nutrition, exercise, sleep, and endocrinology [52:30];
• The effect of estradiol on neurotransmitters in the brain [58:15];
• Options for increasing testosterone in men, and why clomiphene is inferior to exogenous testosterone [1:11:00];
• The rapid drop in progesterone is linked to both premenstrual dysphoric disorder (PMDD) and postpartum depression [1:14:30];
• Treatment of postpartum depression [1:18:00];
• Hypothyroidism presenting as depression: how Linus makes the diagnosis and what he uses for treatment [1:26:00];
• The link between hyperarousal and chronically elevated cortisol [1:39:30];
• A case where the menopause transition uncovers bipolar disorder [1:44:15];
• Ketamine as a tool to treat recalcitrant depression, and concerns about its recreational use [1:49:15];
• Case study: an Alzheimer's patient who improved after psilocybin, and why Linus is cautious about drawing conclusions from it [1:55:15];
• Peter's experience with psychedelics, and the myth that estrogen is bad for men [2:00:30];
• The therapeutic potential of psychedelics in psychiatry [2:11:00]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Aug 17, 2026 2 hr 18 min

#403 ‒ Peptides: separating scientific promise from marketing hype

Episode 403

Show notes

In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent. He then applies this framework to a specific example before examining the risks of gray-market products, concerns about sourcing and quality, and where the field may be headed—ultimately helping listeners distinguish legitimate therapies from hope that has been packaged and sold without sufficient evidence.

We discuss:

• What peptides are and why they must be evaluated individually [3:15];
• A five-question framework for evaluating peptides and other drugs [5:30];
• A three-tier system for classifying the scientific evidence behind peptides [10:00];
• Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks [14:00];
• Why BPC-157's expanding claims do not indicate a broad mechanism [20:45];
• CJC-1295: biological activity versus meaningful clinical benefit [23:30];
• Why testimonials about peptide benefits cannot establish the effectiveness of peptides [27:30];
• The placebo effect, and the importance of controlled trials for evaluating peptides [31:00];
• What FDA approval provides when evaluating peptide safety and effectiveness [34:45];
• Why prescriptions from doctors, compounding pharmacies, and third-party testing do not validate unapproved peptides [38:30];
• Approved peptides sold on the gray market: why evidence for an approved peptide does not automatically extend to gray-market versions [40:45];
• Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented [43:00];
• The promise of peptide science, and the risks of the gray-market wellness industry [46:30];
• Why peptide claims must be falsifiable and why evidence should precede widespread use rather than be expected to catch up later [49:00]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Aug 10, 2026 53 min

#402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.

Episode 402

Show notes

Jim Otvos is a biophysical chemist who pioneered the use of nuclear magnetic resonance (NMR) spectroscopy to measure lipoprotein particles and developed the first FDA-cleared method for directly quantifying LDL particle number (LDL-P), a technology that has since expanded to provide broader insights into metabolic health, inflammation, insulin resistance, and mortality risk. In this episode, Jim recounts the unlikely story of transforming a flawed cancer test into a new way of measuring lipoproteins, explains what standard cholesterol tests can miss and why LDL-P and apoB can inform treatment decisions beyond LDL cholesterol alone, and dispels the misconception that large, "fluffy" LDL particles are benign. He also explores how NMR can reveal insulin resistance before blood sugar rises, GlycA as a marker of chronic low-grade inflammation, and the metabolic vulnerability index (MVX) as a potential measure of frailty, resilience, and mortality risk across the lifespan. Finally, Jim explains why NMR diagnostics remain underused despite the wealth of information they can extract from a single blood test.

We discuss:

• How investigating a flawed 1986 cancer test led to the development of NMR (nuclear magnetic resonance) lipoprotein testing [3:30];
• How standard lipid panels measure cholesterol and triglycerides, and why LDL cholesterol is estimated rather than directly measured [15:15];
• How NMR spectroscopy measures lipoprotein particle size and concentration [20:30];
• Why LDL particle number matters more than particle size, and why large, "fluffy" LDL is not benign [28:45];
• Discordance between LDL cholesterol and LDL particle number: which measure better reflects cardiovascular risk? [36:30];
• How metabolic syndrome and lipid-lowering treatment contribute to the discordance between LDL-C and LDL-P, and the value of particle number for managing risk [45:30];
• Using the NMR-derived LP-IR score to detect insulin resistance and predict type 2 diabetes before glucose rises [51:15];
• The development, commercialization, and uncertain future of the Vantera NMR Analyzer and NMR-based diagnostics [1:04:45];
• The analytical efficiency of NMR testing and the data-driven development of the Metabolic
• Vulnerability Index (MVX) [1:16:00];
• GlycA as an NMR-derived marker of systemic inflammation: its discovery, biological basis, and advantages over hs-CRP [1:25:45];
• Developing the Metabolic Vulnerability Index (MVX): biomarkers of inflammation, malnutrition, muscle wasting, and mortality risk [1:34:00];
• What MVX can tell us about longevity and mortality [1:44:15];
• How MVX may reveal metabolic frailty and predict premature mortality decades in advance in young, healthy adults [1:50:30];
• Potential applications of MVX for predicting treatment response, surgical resilience, and clinical trial outcomes, and the barriers to broader use [2:00:00];
• ApoB versus LDL-P: their clinical similarities, the additional information provided by NMR, and barriers to broader adoption [2:07:30];
• Interpreting the effects of the CETP inhibitor, obicetrapib, on LDL-P, apoB, and small HDL particles [2:13:00];
• The future of NMR diagnostics and MVX: translating scientific potential into broader clinical use [2:20:45]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Aug 3, 2026 2 hr 25 min

#401 ‒ How curiosity transforms medicine: extraordinary discoveries that changed modern healthcare

Episode 401

Show notes

In this episode of The Drive, Peter explores how seemingly obscure basic science discoveries have laid the foundation for some of the most important medical breakthroughs of the past half century. Rather than focusing on the clinical applications of modern therapies, he traces the fascinating stories behind the scientists, experiments, and unexpected discoveries that ultimately led to transformative drug classes, revealing how groundbreaking advances often emerge from research with no obvious clinical goal. Through these historical case studies, Peter provides a new perspective on the unpredictable path of medical innovation and makes the case for why investing in basic scientific research remains essential for driving the next generation of life-changing therapies.

We discuss:

• The discovery of green fluorescent protein (GFP): how curiosity about glowing jellyfish transformed modern biology [2:30];
• Why basic research and nature's biological innovations are the foundation of medical progress [10:45];
• The discovery of statins: how fungi provided the blueprint for cholesterol-lowering drugs [15:15];
• From snake venom to ACE inhibitors: the discovery of a cornerstone therapy for cardiovascular disease [21:00];
• From Yellowstone hot springs to PCR: how Thermus aquaticus transformed modern biology and medicine [28:00];
• The discovery of CRISPR: from salt flats to gene editing and genetic medicine [37:15];
• The discovery of GLP-1 receptor agonists: from Gila monster venom to a new era in metabolic medicine [47:30];
• Why curiosity-driven basic research is essential for the future of medical innovation [54:15]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Jul 27, 2026 1 hr 4 min

#400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risks

Episode 400

Show notes

In this "Ask Me Anything" (AMA) episode, Peter explores the evidence behind environmental pollution and its impact on long-term health, separating well-supported risks from less substantiated claims while providing a practical framework for deciding which exposures deserve attention. He explains what environmental pollution encompasses, where it fits within the broader hierarchy of longevity interventions, and why studying its health effects is uniquely challenging. Peter examines the evidence linking air pollution to disease and shares actionable strategies for improving indoor and outdoor air quality. He also discusses how noise and light pollution can influence sleep, cardiovascular health, and overall well-being, offering practical ways to reduce their effects in daily life. Finally, Peter takes an evidence-based look at electromagnetic fields (EMFs) and 5G technology, evaluating the current science and whether concerns about these exposures are supported by the available data.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feedor our website at the AMA #87 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

• Defining environmental pollution and its role in longevity [1:45];
• Why the topic of environmental pollution is both polarizing and difficult to study [6:00];
• Where environmental exposures fit within the hierarchy of health priorities, and a framework for evaluating which environmental risks are worth addressing [13:15];
• Understanding air pollution: the major pollutants and why PM2.5 is a key marker of health risk [16:00];
• Indoor air pollution: why indoor air quality often matters most for reducing personal air pollution exposure [21:45];
• How air pollution is measured and how the Air Quality Index (AQI) translates pollution data into practical guidance [25:00];
• The health effects of air pollution: evidence linking exposure to respiratory and cardiovascular disease [27:00];
• How air pollution causes disease: biological mechanisms linking pollution to respiratory and cardiovascular health [29:15];
• Who is most susceptible to the health effects of air pollution? [31:45];
• Understanding air pollution thresholds and the differences between WHO and EPA air quality guidelines [34:15];
• Comparing acute air pollution events with chronic exposure and cumulative health risk [36:15];
• Best strategies for mitigating air pollution exposure [38:00];
• Noise pollution: effects on hearing, sleep, and cardiovascular health [44:30];
• Measuring noise exposure and understanding the thresholds for hearing loss and chronic health effects [48:00];
• Practical strategies to reduce noise exposure and protect your hearing [54:15];
• Light pollution: defining light pollution and the importance of timing for circadian health [58:15];
• The health effects of artificial light at night and the evidence behind blue light and blue light-blocking glasses [1:00:00];
• Practical strategies for optimizing light exposure to support circadian rhythms and sleep [1:04:00];
• Concerns about EMF and 5G exposure: understanding electromagnetic fields and the distinction between ionizing and non-ionizing radiation [1:06:30];
• Evaluating the evidence linking radiofrequency electromagnetic fields to cancer risk [1:10:15];
• Evaluating the evidence for electromagnetic hypersensitivity and EMF-related symptoms [1:14:00];
• Practical recommendations for managing everyday EMF and 5G exposure and avoiding unnecessary interventions [1:15:30];
• Prioritizing environmental exposures based on their impact on health and longevity [1:18:00];
• The highest-ROI strategies for reducing environmental pollution exposure and protecting long-term health [1:19:30]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Jul 20, 2026 20 min

#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

Episode 399

Show notes

Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care.

We discuss:

• Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45];
• How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15];
• The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30];
• Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45];
• Why forgetting names is usually normal and when word-finding problems become concerning [29:00];
• Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45];
• The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15];
• When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00];
• Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15];
• Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45];
• The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00];
• How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30];
• Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30];
• A multimodal approach to Alzheimer's treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00];
• Vascular dementia, Lewy body dementia, and the overlap with Alzheimer's disease [1:21:00];
• Lewy body dementia and Parkinson's disease: distinguishing two alpha-synuclein disorders [1:26:45];
• Risk factors for Lewy body dementia and what remains unknown [1:36:15];
• Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45];
• How biomarkers changed Gayatri's perspective on the potential for Alzheimer's patients to improve [1:47:15];
• The future of Alzheimer's care: AI, precision medicine, and personalized treatment [1:49:30]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Jul 13, 2026 1 hr 57 min

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

Show notes

In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably.

We discuss:

• Peter's humorous experience talking nutrition with a second grader [3:00];
• Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:30];
• Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:45];
• The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [11:00];
• Grip strength as a simple yet powerful predictor of all-cause mortality [17:15];
• Is muscle strength causal or just a marker of health? [20:30];
• Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [23:00];
• How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [24:15];
• How muscle mass and strength decline with age, and why it's essential to act early to slow decline and preserve function later in life [31:00];
• The foundational principles of building muscle strength and size through resistance training [36:00];
• How to apply "progressive overload" for long-term strength and muscle gains [40:00];
• The difference between concentric and eccentric muscle contractions and how each impacts strength, hypertrophy, and injury prevention [45:15];
• The differences between muscle fiber types, and how aging disproportionately affects fast-twitch fibers responsible for power [50:45];
• How to effectively train for power [52:30];
• Training intensity: the benefits and safety of using the "reps in reserve" method [53:30];
• How to balance compound and isolation exercises in a workout routine, and why compound lifts are foundational [56:15];
• Can bodyweight exercises build muscle as effectively as weight training? [58:15];
• How women can effectively build strength and muscle: key considerations [59:45];
• Effective methods for tracking progress in strength [1:01:45];
• Effective methods for tracking progress in muscle mass, and how to interpret results from a DEXA scan [1:05:00];
• How to balance workout frequency with recovery for optimal results [1:07:15];
• How to recognize signs of overtraining and when to consider taking rest days [1:10:45];
• Avoiding injury: how beginners or returning lifters can start resistance training safely [1:15:45];
• Protein: recommended intake, quality sources, timing of consumption, and more [1:18:00];
• How fasting and calorie restriction affect muscle mass and what can be done to minimize muscle loss [1:24:45];
• Key nutritional factors beyond protein that support muscle growth: hydration, creatine, and recovery [1:28:15];
• The impact of hormones, sleep, stress, and consistency on muscle building and recovery [1:29:15];
• How to structure an effective workout routine for a younger person who is new to resistance training [1:32:00];
• How to modify beginner resistance training programs for older individuals to prioritize safety and gradual progress [1:36:00];
• Should beginners start with machines or free weights when resistance training? [1:37:00];
• How experienced lifters should modify their training to support healthspan and performance in later life [1:38:30]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Jul 6, 2026 1 hr 44 min

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

Episode 398

Show notes

In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feedor our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

• The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45];
• Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45];
• How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15];
• Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30];
• Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15];
• The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00];
• Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45];
• Why lean mass measurements are an imperfect proxy for muscle health and function [21:45];
• The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00];
• Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00];
• Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00];
• Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45];
• Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00];
• Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00];
• Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45];
• Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15];
• Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00];
• The risks of using gray-market retatrutide before FDA approval [52:15];
• Key takeaways [54:30]; and
• More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Jun 29, 2026 10 min

#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.

Episode 397

Show notes